Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Cancer survivors at greater risk of subsequent primary cancers
  • News

Cancer survivors at greater risk of subsequent primary cancers

  • 30 December 2020
  • Janet Fricker
Cancer survivors at greater risk of subsequent primary cancers
Total
0
Shares
0
0
0
0
0

Survivors of adult-onset cancers run a greater risk of developing and dying from subsequent primary cancers (SPCs) than the general population. The retrospective cohort study, reported in JAMA (December 22), found cancers associated with smoking or obesity comprised the majority of the secondary cancers.

“These findings reinforce the importance of coordinated efforts by primary care clinicians to mitigate the risks of SPCs through survivorship care, with greater focus on lifestyle factors, including smoking cessation, weight management, physical activity, and healthy eating as receipt of counselling or treatment (tobacco only) to aid the adoption of healthy habits,” says Ahmedin Jemal, the senior author.

For the study, Jemal, from the American Cancer Society (Atlanta, Georgia) and colleagues analysed data on nearly 1.54 million cancer survivors from 1992 to 2017 using 12 Surveillance, Epidemiology and End Results (SEER) registries in the US. The analysis, involving survivors aged between 20 and 84 years who had lived for at least five years after initial diagnosis, estimated the increased risk for SPC using standardised incidence ratio (SIR) and standardised mortality ratio (SMR) versus the general population. The category of SPCs included all new primary cancers except same-type cancers and non-melanoma skin cancer.

Results showed the total number of SPCs observed in the entire cohort was 156,442 during 11,197,890 person-years of follow-up, resulting in an overall incidence of approximately 10%.

Among male survivors, there were 49,065 cases of SPC (177 per 10,000 person-years) leading to 28,463 deaths (104 per 10,000 person-years), and among female survivors there were 62,348 cases (109 per 10,000 person-years) and 34,879 resultant deaths (62 per 10,000 person-years). In comparison to the general population, male survivors had an 11% higher risk of developing SPCs (SIR=1.11, 95%CI 1.10−1.12) and a 45% higher risk of dying from SPCs (SMR=1.45, 95%CI 1.43−1.46). Female survivors had a 10% higher risk of developing SPCs (SIR=1.10, 95%CI 1.09−1.11) and a 33% higher risk of dying from SPCs (SMR=1.33, 95%CI 1.32−1.34).

Furthermore, investigators found men who survived laryngeal cancer ran the greatest risk of developing an SPC (SIR=1.75), while men who survived gall bladder cancer ran the greatest risk of dying from an SPC (SMR=3.82). Among women, survivors of laryngeal and oesophageal cancers ran the greatest risk of developing SPCs (SIR=2.48 for both) and survivors of oesophageal cancer ran the greatest risk of dying from an SPC (SMR=4.56).
Among survivors of all cancers, four common smoking-related SPCs (lung, urinary bladder, oral cavity/pharynx, and oesophagus) accounted for 26% to 45% of the total SPC incidence and mortality, while four common obesity-related cancers (colorectum, pancreas, corpus uteri, and liver) comprised 22% to 26% of total SPC mortality.

In an accompanying editorial, Patricia Ganz and Jacqueline Casillas, both from UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, write, “The frequency with which SPCs occur after a wide variety of cancer diagnoses, and the higher relative risk of dying from an SPC, suggest that primary care clinicians should routinely consider the risk of SPCs in all the cancer survivors in their clinical practice.” The five-year survival time point, they add, often marks the clinical transition when patients are no longer followed up in oncology specialty practices and must rely on their primary care clinicians as their main source of medical care.

In the second accompanying editorial, Domingo Perez, from Mayo Clinic (Rochester, Minnesota) Charles Loprinzi and Kathryn Ruddy, write, “Additional research is necessary to clarify the not always straightforward connections between first and second primary cancers, which are probably mediated by complex interactions between them and genetic predispositions (including both high-penetrant gene mutations and low-penetrant gene polymorphisms), ageing, immune status, treatment exposures, lifestyle factors, race, sex, socioeconomic status, and access to health care.”

To identify potential targets for intervention, they add, assessing the primary contributors to poor outcomes in patients with second malignant diseases will be important.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • cancer survivors
  • risk
  • Subsequent primary
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Medicine

Highlights of 2020 San Antonio Breast Cancer Symposium

  • 28 December 2020
  • Janet Fricker
View Post
Next Article
Interview to Christian Rolfo
  • Interviews to the Expert

Liquid biopsy for early stage lung cancer moves closer

  • 12 January 2021
  • Alberto Costa
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.